The association of race, comorbid anxiety, and antidepressant adherence among Medicaid enrollees with major depressive disorder

Research in Social and Administrative Pharmacy

Volumn 8, Issue 3, 2012, Pages 193-205

  Wu, Chung Hsuen ^a   Erickson, Steven R ^b   Piette, John D ^c,d   Balkrishnan, Rajesh ^b  

^a University of North Carolina   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

Adherence; African Americans; Comorbid anxiety disorders; Major depressive disorders; Medicaid; Race

Indexed keywords

ANTIDEPRESSANT AGENT;

ADOLESCENT; ADULT; AFRICAN AMERICAN; ANXIETY; ARTICLE; ATTITUDE TO HEALTH; CAUCASIAN; COMORBIDITY; CROSS-SECTIONAL STUDY; ETHNOLOGY; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR DEPRESSION; MALE; MEDICAID; MIDDLE AGED; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODEL; PSYCHOLOGICAL ASPECT; RETROSPECTIVE STUDY; RISK; RISK ASSESSMENT; RISK FACTOR; UNITED STATES;

ADOLESCENT; ADULT; AFRICAN AMERICANS; ANTIDEPRESSIVE AGENTS; ANXIETY; COMORBIDITY; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER, MAJOR; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEDICAID; MEDICATION ADHERENCE; MIDDLE AGED; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84860833632     PISSN: 15517411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sapharm.2011.04.002     Document Type: Article

References (59)

1. Anderson I.M., Ferrier I.N., Baldwin R.C., et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008, 22(4):343-396.
2. Kessler R.C., Chiu W.T., Demler O., Merikangas K.R., Walters E.E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62(6):617-627.
3. Kessler R.C., Berglund P., Demler O., Jin R., Merikangas K.R., Walters E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62(6):593-602.
4. Olfson M., Shea S., Feder A., et al. Prevalence of anxiety, depression, and substance use disorders in an urban general medicine practice. Arch Fam Med 2000, 9(9):876-883.
5. Asnaani A., Richey J.A., Dimaite R., Hinton D.E., Hofmann S.G. A cross-ethnic comparison of lifetime prevalence rates of anxiety disorders. J Nerv Ment Dis 2010, 198(8):551-555.
6. Breslau J., Aguilar-Gaxiola S., Kendler K.S., Su M., Williams D., Kessler R.C. Specifying race-ethnic differences in risk for psychiatric disorder in a USA national sample. Psychol Med 2006, 36(1):57-68.
7. Himle J.A., Baser R.E., Taylor R.J., Campbell R.D., Jackson J.S. Anxiety disorders among African-Americans, blacks of Caribbean descent, and non-Hispanic whites in the United States. J Anxiety Disord 2009, 23(5):578-590.
8. Hasin D.S., Goodwin R.D., Stinson F.S., Grant B.F. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry 2005, 62(10):1097-1106.
9. Kessler R.C., Berglund P., Demler O., et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289(23):3095-3105.
10. Felker B.L., Hedrick S.C., Chaney E.F., et al. Identifying depressed patients with a high risk of comorbid anxiety in primary care. Prim Care Companion J Clin Psychiatry 2003, 5(3):104-110.
11. Sherbourne C.D., Wells K.B. Course of depression in patients with comorbid anxiety disorders. J Affect Disord 1997, 43(3):245-250.
12. Clayton P.J., Grove W.M., Coryell W., Keller M., Hirschfeld R., Fawcett J. Follow-up and family study of anxious depression. Am J Psychiatry 1991, 148(11):1512-1517.
13. Fava M., Uebelacker L.A., Alpert J.E., Nierenberg A.A., Pava J.A., Rosenbaum J.F. Major depressive subtypes and treatment response. Biol Psychiatry 1997, 42(7):568-576.
14. Trivedi M.H. Tools and strategies for ongoing assessment of depression: a measurement-based approach to remission. J Clin Psychiatry 2009, (70 suppl 6):26-31.
15. Cramer J.A., Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998, 49(2):196-201.
16. Lin E.H., Von Korff M., Katon W., et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 1995, 33(1):67-74.
17. Olfson M., Marcus S.C., Tedeschi M., Wan G.J. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry 2006, 163(1):101-108.
18. Bogner H.R., Lin J.Y., Morales K.H. Patterns of early adherence to the antidepressant citalopram among older primary care patients: the prospect study. Int J Psychiatry Med 2006, 36(1):103-119.
19. Brown C., Schulberg H.C., Sacco D., Perel J.M., Houck P.R. Effectiveness of treatments for major depression in primary medical care practice: a post hoc analysis of outcomes for African-American and white patients. J Affect Disord 1999, 53(2):185-192.
20. Gellad W.F., Haas J.S., Safran D.G. Race/ethnicity and nonadherence to prescription medications among seniors: results of a national study. J Gen Intern Med 2007, 22(11):1572-1578.
21. Gerber B.S., Cho Y.I., Arozullah A.M., Lee S.Y. Racial differences in medication adherence: a cross-sectional study of Medicare enrollees. Am J Geriatr Pharmacother 2010, 8(2):136-145.
22. Sleath B., Domino M.E., Wiley-Exley E., Martin B., Richards S., Carey T. Antidepressant and antipsychotic use and adherence among Medicaid youths: differences by race. Community Ment Health J 2010, 46(3):265-272.
23. Han E., Liu G.G. Racial disparities in prescription drug use for mental illness among population in US. J Ment Health Policy Econ 2005, 8(3):131-143.
24. Harman J.S., Edlund M.J., Fortney J.C. Disparities in the adequacy of depression treatment in the United States. Psychiatr Serv 2004, 55(12):1379-1385.
25. Melfi C.A., Croghan T.W., Hanna M.P., Robinson R.L. Racial variation in antidepressant treatment in a Medicaid population. J Clin Psychiatry 2000, 61(1):16-21.
26. Stein M.B., Cantrell C.R., Sokol M.C., Eaddy M.T., Shah M.B. Antidepressant adherence and medical resource use among managed care patients with anxiety disorders. Psychiatr Serv 2006, 57(5):673-680.
27. ® USER GUIDE: Multi-State Medicaid Database 2007, Thomson Reuters, Thomson Reuters, Ann Arbor, MI.
28. Ray W.A. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003, 158(9):915-920.
29. Balkrishnan R., Arondekar B.V., Camacho F.T., Shenolikar R.A., Horblyuk R., Anderson R.T. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus. Clin Ther 2007, (29 Spec No):1306-1315.
30. Shenolikar R.A., Balkrishnan R., Camacho F.T., Whitmire J.T., Anderson R.T. Comparison of medication adherence and associated health care costs after introduction of pioglitazone treatment in African-Americans versus all other races in patients with type 2 diabetes mellitus: a retrospective data analysis. Clin Ther 2006, 28(8):1199-1207.
31. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 2010; Available at: , Accessed April 15, 2011. http://www.psychiatryonline.com/pracGuide/PracticePDFs/PG_Depression3rdEd.pdf.
32. University of Michigan Health System. Guidelines for clinical care: depression. 2005; Available at: , Accessed April 15, 2011. http://www.med.umich.edu/1info/FHP/practiceguides/depress/depress05.pdf.
33. Hess L.M., Raebel M.A., Conner D.A., Malone D.C. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006, 40(7-8):1280-1288.
34. Karve S., Cleves M.A., Helm M., Hudson T.J., West D.S., Martin B.C. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care 2008, 46(11):1125-1133.
35. Vanderpoel D.R., Hussein M.A., Watson-Heidari T., Perry A. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis. Clin Ther 2004, 26(12):2066-2075.
36. Karve S., Cleves M.A., Helm M., Hudson T.J., West D.S., Martin B.C. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 2009, 25(9):2303-2310.
37. Cramer J.A., Roy A., Burrell A., et al. Medication compliance and persistence: terminology and definitions. Value Health 2008, 11(1):44-47.
38. Linden M., Gothe H., Dittmann R.W., Schaaf B. Early termination of antidepressant drug treatment. J Clin Psychopharmacol 2000, 20(5):523-530.
39. Mullins C.D., Shaya F.T., Meng F., Wang J., Bron M.S. Comparison of first refill rates among users of sertraline, paroxetine, and citalopram. Clin Ther 2006, 28(2):297-305. discussion 296.
40. Mullins C.D., Shaya F.T., Meng F., Wang J., Harrison D. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram. Pharmacotherapy 2005, 25(5):660-667.
41. Hansen R.A., Dusetzina S.B., Dominik R.C., Gaynes B.N. Prescription refill records as a screening tool to identify antidepressant non-adherence. Pharmacoepidemiol Drug Saf 2010, 19(1):33-37.
42. Andersen R.M. National health surveys and the behavioral model of health services use. Med Care 2008, 46(7):647-653.
43. Andersen R.M., Davidson P.L. Improving access to care in America. Change the U.S. Health Care System: Key Issues in Health Services Policy and Management 2007, 3-32. Jossey-Bass, San Francisco, CA. R.M. Andersen, T.H. Rice, G.F. Kominski (Eds.).
44. Andersen R., Newman J.F. Societal and individual determinants of medical care utilization in the United States. Milbank Mem Fund Q Health Soc 1973, 51(1):95-124.
45. Andersen R.M. Revisiting the behavioral model and access to medical care: does it matter?. J Health Soc Behav 1995, 36(1):1-10.
46. Elixhauser A., Steiner C., Harris D.R., Coffey R.M. Comorbidity measures for use with administrative data. Med Care 1998, 36(1):8-27.
47. SAS/STAT 9.1 User's Guide 2004, SAS Institute Inc, SAS Institute Inc., Cary, NC.
48. Alegria M., Chatterji P., Wells K., et al. Disparity in depression treatment among racial and ethnic minority populations in the United States. Psychiatr Serv 2008, 59(11):1264-1272.
49. Grunebaum M.F., Oquendo M.A., Manly J.J. Depressive symptoms and antidepressant use in a random community sample of ethnically diverse, urban elder persons. J Affect Disord 2008, 105(1-3):273-277.
50. Miranda J., Cooper L.A. Disparities in care for depression among primary care patients. J Gen Intern Med 2004, 19(2):120-126.
51. Cooper L.A., Gonzales J.J., Gallo J.J., et al. The acceptability of treatment for depression among African-American, Hispanic, and white primary care patients. Med Care 2003, 41(4):479-489.
52. Cooper-Patrick L., Powe N.R., Jenckes M.W., Gonzales J.J., Levine D.M., Ford D.E. Identification of patient attitudes and preferences regarding treatment of depression. J Gen Intern Med 1997, 12(7):431-438.
53. Mood disorders: pharmacologic prevention of recurrences. Consensus Development Panel. Am J Psychiatry 1985, 142(4):469-476. NIMH/NIH Consensus Development Conference statement.
54. McGuire T.G., Miranda J. New evidence regarding racial and ethnic disparities in mental health: policy implications. Health Aff (Millwood) 2008, 27(2):393-403.
55. Marwaha S., Livingston G. Stigma, racism or choice. Why do depressed ethnic elders avoid psychiatrists?. J Affect Disord 2002, 72(3):257-265.
56. Brown C., Battista D.R., Bruehlman R., Sereika S.S., Thase M.E., Dunbar-Jacob J. Beliefs about antidepressant medications in primary care patients: relationship to self-reported adherence. Med Care 2005, 43(12):1203-1207.
57. Delgado P.L. Approaches to the enhancement of patient adherence to antidepressant medication treatment. J Clin Psychiatry 2000, (61 suppl 2):6-9.
58. Russell J., Kazantzis N. Medication beliefs and adherence to antidepressants in primary care. N Z Med J 2008, 121(1286):14-20.
59. Balkrishnan R. The importance of medication adherence in improving chronic-disease related outcomes: what we know and what we need to further know. Med Care 2005, 43(6):517-520.